Fig. 7
Enhanced radiosensitivity of NPC by OL requires miR-519d. a and b Using the MISSION Lenti miR-519d Inhibitor kit, NPC HNE-1 (a) and HONE-1 (b) stably expressing miR-519d inhibitor (anti-miR-519d) or control, respectively, were incubated for 24 h with media containing 200 μM of OL, with 0 μM OL treatment as control, and then subjected to radiation dosage as indicated. c and e Growth curve of HNE-1 (c) and HONE-1 (d) xenograft tumors expressing miR-519d inhibitor (anti-miR-519d) or control, respectively, in mice after OL treatment, with no OL administration as control (n = 10 each). e At the end of animal studies (day 21), xenograft tumors were harvested to examine the expressions of miR-519d following respective treatments as shown. Values were expressed as mean ± SD. * p < 0.05, ** p < 0.01, compared to both 0 μM/no OL and OL + control